Quarterly ResultAug 5, 2026, 04:03 PM
Arcutis Q2 Revenue $129.9M, +59%; Raises FY26 Guidance to $525M-$540M
AI Summary
Arcutis Biotherapeutics reported strong Q2 2026 financial results with net product revenue of $129.9 million, a 59% increase year-over-year. The company raised its full-year 2026 net product sales guidance to $525 million–$540 million. Key developments include FDA approval for ZORYVE cream 0.3% for plaque psoriasis in children down to age 2, and FDA acceptance of an sNDA for ZORYVE cream 0.05% for infants with atopic dermatitis, with a target action date of February 23, 2027. The company also maintained positive operating cash flow and advanced its pipeline.
Key Highlights
- Q2 2026 net product revenue was $129.9 million, up 59% YoY and 23% sequentially.
- Raised 2026 full-year net product sales guidance to $525 million–$540 million.
- Received FDA approval for ZORYVE cream 0.3% for plaque psoriasis in children down to age 2.
- FDA accepted sNDA for ZORYVE cream 0.05% for infants with atopic dermatitis; PDUFA date Feb 23, 2027.
- Completed enrollment for Phase 2 vitiligo trial; results expected Q4 2026.
- Net income was $15.0 million ($0.11 EPS) in Q2 2026, compared to a net loss last year.
- Generated $12.6 million in positive operating cash flow for Q2 2026.
- SG&A expenses increased to $82.1 million due to sales force expansion.
Price Impact
More from ARQT